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Abstract 
 
Neuropeptides are small peptides that act as signalling molecules. These have a 
wide range of important roles in numerous physiological, metabolic and behaviour 
functions. For example, oxytocin and vasopressin have essential roles in salt 
balance, social behaviour, and stress regulation. The role of neuropeptides in 
reproduction is well documented: it has been demonstrated they are involved in 
sexual behaviour, maternal-infant bonding, pair-bonding, lactation, pregnancy, 
penile erection, ejaculation, uterus contraction, and sperm transfer. The receptors 
for neuropeptides are found throughout both the male and female reproductive 
tracts. Several neuropeptides are found in both seminal plasma and follicular fluid 
indicating some involvement directly in fertilisation. Neuropeptide levels are altered 
in mood disorders and these altered levels could potentially have implications in 
infertility. However, very little is currently known about the effects of neuropeptides 
on sperm function, this study explored this area further.  
Considering the overarching link that neuropeptides have between pair bonding, 
mental health and fertility it was hypothesised that any perturbations in their action 
may impede successful reproduction. This study investigated how neuropeptides 
could regulate sperm function. These data may lead to future therapies in assisted 
reproduction. 
Semen samples were produced by masturbation, separated from the seminal 
plasma and probed for neuropeptide receptors via immunocytochemistry. This is the 
first time, to knowledge, that vasopressin receptor 2 has been localised on human 
sperm. As no other receptors were localised this study focused on any effect 
vasopressin may have on sperm function by incubation with a vasopressin agonist 
and measuring any modulations in motility and PKA phosphorylation activity.  
No significant differences were found in motility or PKA phosphorylation activity in 
sperm treated with vasopressin agonist, further optimisation of the assays is 
required. 
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1.0 Introduction 
 
The neuroendocrine system is responsible for regulating a vast number of functions; 
homeostasis, metabolism, thirst, hunger, sleep, behaviour, mood and reproduction. 
It comprises of the hypothalamus as a link from the nervous system to the endocrine 
system through the pituitary.  
Mood has been implicated in infertility. Stress, depression and anxiety have been 
shown to negatively impact both male and female fertility. Neuropeptides and their 
receptors are found throughout the limbic system such as amygdala and 
hypothalamus and are important in mood regulation; differing levels of 
neuropeptides in the blood have been implicated in mood disorders such as 
postpartum depression providing an important link between neuropeptides, 
reproduction and mood. 
Neuropeptides are involved throughout all phases of reproduction, from sexual 
behaviour, to conception, to lactation and parent-infant bonding and the receptors 
are found throughout both the male and female reproductive tracts. Several 
neuropeptides are found in both seminal plasma and follicular fluid indicating some 
involvement directly in fertilisation. Neuropeptide levels are altered in mood 
disorders and these altered levels could potentially have implications in infertility. 
 
1.1 Neuropeptides  
 
Neuropeptides are short chain polypeptides. They are peptides that function as 
neurotransmitters and some can also function in the periphery as peptide hormones 
for example, oxytocin, vasopressin, prolactin corticotropin-releasing hormone and 
ghrelin. However, unlike neurotransmitters they are not re-absorbed by the cell and 
hence once secreted typically have more prolonged actions. They influence a 
variety of biological processes such as, reward, metabolism, analgesia, memory, 
appetite, behaviour and also reproduction (Mac E Hadley, 1996). 
The majority of neuropeptides function through G protein-coupled receptors for 
instance both oxytocin and vasopressin, these are a group of cell surface receptors, 
when activated by the binding of the neuropeptide, activate the heterotrimeric G 
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proteins inducing an intracellular signalling cascade resulting in a cellular response 
(Gomes et al., 2013). 
 
1.2 Neuropeptides in reproduction  
 
Neuropeptides are important in all aspects of reproduction, from pair bonding, 
sexual behaviour, penile erection, both male and female orgasm and sperm transfer 
to pregnancy and parturition to lactation and maternal-infant bonding (Filippi et al., 
2002; Fuchs et al., 1990).  
The involvement of neuropeptides in reproduction is most evident in the female 
where, for instance both oxytocin and prolactin are vital in pregnancy and during 
birth (Nissen et al., 1996; Uvnäs-Moberg et al., 1990), and neuropeptide Y has been 
implicated in fertility regulation and has been shown to suppress fertility in female 
fats (Toufexis et al., 2002, Roa and Herbison, 2012). Other neuropeptides have also 
been shown to be related to female fertility, pituitary adenylate cyclase-activating 
polypeptide (PACAP) has been shown to reduce fertility in female mice via reduced 
maternal behaviour and smaller little sizes (Shintani et al., 2002).  
Murgatroyd and Nephew, (2013) demonstrated that early life chronic stress has 
longitudinal effects and reduced maternal behaviour and nursing efficiency in adult 
female rats. This was specifically associated with attenuated gene expression for 
the neuropeptides vasopressin, oxytocin and prolactin in the brain. 
Depression and chronic anxiety not only negatively affect the mother but also their 
adult offspring, vasopressin, oxytocin and prolactin were implicated in the aetiology 
of both stress related mood disorders and maternal behaviour for both humans and 
rodents. Low levels of oxytocin and prolactin have been associated with postpartum 
depression (Abou-Saleh et al., 1998; Skrundz et al., 2011) and the opposite is true 
for vasopressin, high levels of vasopressin are associated with depression in 
humans and in animal models of depression (Murgatroyd et al., 2004,  Rotzinger et 
al., 2010, Surget and Belzung, 2008). 
In regards to sperm function, Gonzales (1989) found prolactin released from the 
seminal vesicles directly stimulate sperm motility and negatively impacted 
concentration. In animal studies vasopressin has been found to negatively affect 
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sperm motility and overall function (Kwon et al., 2013). Oxytocin levels have been 
found to elevate significantly post ejaculation however, no correlation was found 
between oxytocin levels and sperm motility and quality and it was postulated that in 
humans it is primarily involved in the precipitation of ejaculation (Ogawa et al., 
1980). In domestic animal breeding studies oxytocin has been shown to aid sperm 
transport when added to semen preparations during artificial insemination (Okazaki 
et al., 2014). 
 
Although there are several neuropeptides involved in reproduction there were three 
of particular interest. Oxytocin, prolactin and vasopressin are well documented in 
literature for their integral roles in mood, sexual behaviour and sperm transport and 
reproduction, and their receptors are found throughout male and female 
reproductive tracts and tissues (Filippi et al., 2002; Fuchs et al., 1990; Ouhtit et al., 
1993). 
1.3. Oxytocin  
 
Oxytocin is a nonapeptide (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2), which is 
synthesised in the hypothalamus and secreted from posterior pituitary (Norman and 
Henry, 2015). Oxytocin is associated with pregnancy and parturition – stimulating 
uterine contractions, and is involved in lactation. Studies have shown , that knockout 
mice have no ability to lactate (Zingg and Laporte, 2003). Oxytocin has been found 
to increase maternal behaviour (mother-offspring bonding), female-male pair-
bonding and sexual behaviour, i.e. lordosis behaviour and increases duration and 
frequency of mating. In other studies, oxytocin was shown to increases maternal 
aggression in mice. However, there are conflicting reports for the effects on male 
aggression (Caldwell and Young III, 2006). In female mice progesterone has been 
found to directly inhibit oxytocin by having a high affinity for the oxytocin receptor, 
resulting in uterine quiescence (low myometrium contractibility) (Gimpl and 
Fahrenholz, 2001). 
The oxytocin receptor is a type I G protein-coupled receptor, primarily Gq that 
activates the phospholipase C pathway (Figure 1). Oxytocin binds to its receptor, 
activating phospholipase C (PLC) which hydrolyses phosphatidylinositol 4,5-
bisphosphate (PIP2) into diacyl glycerol (DAG) and inositol 1,4,5-triphosphate (IP3). 
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IP3 binds to its receptors causing an influx of calcium into the cell while DAG remains 
membrane bound, together IP3 and DAG activate protein kinase C (PKC) which 
goes on to phosphorylate target proteins. In the central nervous system oxytocin 
and its receptor is widely distributed in a variety of areas in the brain, hypothalamus, 
ventral hippocampus, amygdala, olfactory bulbs. The neuropeptide and its receptor 
is found throughout both male and female reproductive tracts, for example in the 
pregnant uterus, placenta, ovaries, corpus luteum, testis, leydig cells, epididymis, 
prostate, mammary tissues, for review see (Gimpl and Fahrenholz, 2001). 
Oxytocin use in intrauterine insemination in farm animals has been shown to aid 
sperm transport (Gibson et al., 2004; Langendijk et al., 2005). However, there have 
been conflicting findings in other animal studies using intrauterine insemination, 
where the use of oxytocin had no effect on fertility and fertilisation rates (Sayre and 
Lewis, 1997). In humans it has been suggested that oxytocin also aids sperm 
transport via contractility of the uterus acting as a peristaltic pump that aids the 
transport of sperm towards the ovary with the dominant follicle (Wildt et al., 1998). 
 
Figure 1. Oxytocin signalling cascade via G protein-coupled receptor, Gq alpha subunit. 
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1.3.2 Prolactin  
 
Prolactin has a wide range of biological actions, such as: metabolism, 
immunoprotection, growth, water and electrolyte balance, behaviour and 
reproduction. The receptor is a member of a subfamily of hematopoietic cytokine 
receptors (Norman and Henry, 2015). The prolactin receptor has been localised in 
a variety of tissues and cells; mammary gland, throughout the reproductive organs, 
the central nervous system, pituitary, skin, lungs, adrenal cortex, liver, heart, 
gastrointestinal tract, bone, pancreas, lymphoid tissues, kidney and sperm as well 
as a variety of cancer cells (Tsai-Morris, Dufau, 2004; Pujianto et al., 2010). 
Prolactin plays a vital role in cell proliferation and by working synergistically with 
growth hormone to stimulate this proliferation and differentiation. In animals with 
seasonal reproduction it has been shown that there are seasonal fluctuations in 
prolactin, peaking during breeding season (Curlewis, 1992). 
The prolactin receptor is a type 1 cytokine receptor that activates the JAK/STAT, 
PI3K/AKT/mTOR (cell cycle regulation) pathway (Brooks et al., 2014, Helmer et al., 
2010). The JAK/STAT pathway is involved in myriad cell signalling and is highly 
conserved, it also regulates gene expression via ligand-specific signal pathways and 
mediating chromatin modifications and communicating with the core promotors. The 
relevant cytokine binding to the cell surface receptor which activates the relevant 
JAKs, these phosphorylate tyrosine residues on the cytokine receptor and form a 
binding site for molecules with SH2 domains, the SH2 domains that possess STATs 
are also phosphorylated by JAKs and form hetero/homodimers which translocate to 
the nucleus and activate transcription of target genes (Aaronson and Horvath, 
2002). The PI3K/AKT/mTOR pathway is directly related to cell proliferation, 
quiescence and cancers, commonly in cancers this pathway is overactive and leads 
to inhibition of apoptosis. This pathway, in short, functions by activating 
phosphoinositide 3-kinase (PI3K) which activates protein kinase B (AKT) which in 
turn activates mechanistic target of rapamycin (mTOR), this regulates processes 
such as autophagy, protein synthesis, cell survival/growth and cell motility 
(Clevenger et al., 2003, Hay and Sonenberg, 2004).  
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Figure 2. Prolactin signalling cascade via type 1 cytokine receptor. 
 
1.3.3 Vasopressin 
 
A nonapeptide (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2) that is synthesised in 
the hypothalamus and secreted from posterior pituitary. Vasopressin is structurally 
very similar to oxytocin. Both are constituted of 9 amino acids, only 2 of these 9 
differ between oxytocin and vasopressin (Norman and Henry, 2015).  
Vasopressin has been implicated in corpus luteum function in conjunction with 
oxytocin in animal studies, porcine corpora lutea were collected at a variety of 
stages through the oestrous cycle and fluctuations of vasopressin, oxytocin and 
progesterone were measured. It was observed that concentrations of oxytocin and 
vasopressin were essentially similar until the end of the cycle where a significant 
increase of vasopressin was detected (Choy and Watkins, 1988). Injections of 
vasopressin into the cauda epididymis of rats showed potential as a male 
contraceptive, where all doses used caused oligozoospermic (low sperm 
concentration) ejaculation with the higher dose producing teratozoospermia 
(abnormal sperm morphology) ejaculation, while sexual behaviour remained 
unaffected (Ratnasooriya and Jayakody, 2005).  
The vasopressin receptor 2 is a G protein-coupled receptor (Gs alpha subunit - the 
cAMP dependent pathway), which activates adenylyl cyclases converting ATP to 
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cyclic AMP (cAMP) thus activating protein kinase A which leads to phosphorylation 
of target proteins (Holmes et al., 2003).  
 
Figure 3. Vasopressin signalling cascade via vasopressin receptor 2. 
Although the role of neuropeptides in reproduction is very well documented, there 
is little known about the role of neuropeptides on sperm function. 
 
1.4 Sperm biology  
 
1.4.1 Sperm structure 
 
The structure of sperm is a highly specialised cell with the function of delivering the 
haploid paternal genome to the oocyte. The sperm can be apportioned into three 
major sections; the head, the midpiece and the tail. The head of the sperm contains 
the haploid paternal genome and is surrounded by the acrosome that contains vital 
enzymes such as acrosin that digest the zona pellucida allowing sperm to enter the 
perivitelline space and enable sperm-oocyte fusion. The midpiece contains 
mitochondria for ATP production and the energy source for motility. The tail 
executes the movement propelling the sperm through the female reproductive tract 
towards the oocyte. 
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Figure 4. Sperm structure. Representation of main components of the sperm. 
 
1.4.2 Spermatogenesis / maturation 
 
Sperm are produced in the testis during the process of spermatogenesis; this 
process starts at puberty and normally continues throughout the male’s life (Figure 
5). 
The whole process of spermatogenesis itself is a lengthy process that takes just 
over 70 days. Beginning with spermatogonia, the initial cells in this process, 
replicate at first via mitosis into primary spermatocytes and then via meiosis I to 
produce secondary spermatocytes and these divide again via meiosis II the haploid 
round cell spermatids. Next, the spermatids undergo spermiogenesis; this process 
alters the cell from round cell into flagellated cell, development of the acrosome and 
the tail as well as an increase in nuclear condensation to produce spermatozoa. 
However, these sperm lack motility and must undergo further maturation in the 
epididymis (Coward and Wells, 2013; Moore, 1998; Ruwanpura et al., 2010). 
In brief, the epididymis is a coiled tube responsible for storage, maturation and 
transportation of sperm between the testes and the vas deferens. It consists of three 
different sections, the caput or head, corpus or body and cauda or tail. It takes 
approximately two weeks for sperm to pass through the epididymis and undergo 
maturation. Sperm undergo many essential morphological and functional changes 
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during their passage through the epididymis including, modification of the chromatin, 
acrosome and gain the ability to become motile and fertilise the oocyte (Clulow et 
al., 1994; Hamilton et al., 1969; Hess, 2000; Overstreet and Cooper, 1978).  
 
Figure 5. Spermatogenesis. Basic representation of the process of spermatogenesis. 
1.4.3 Sperm function  
 
Sperm must undergo biochemical and physical changes in order to successfully 
fertilise an oocyte. One important process is capacitation. 
Capacitation comprises a reversible set of physiological changes that involve the 
removal of cholesterol by albumin in the female reproductive tract and a prerequisite 
for hyperactivation (see below) and the acrosome reaction. In vivo, it involves the 
removal of inhibitory factors from seminal plasma and the interaction of the sperm 
with components in the female reproductive tract (Jaiswal and Eisenbach, 2002). 
The removal of cholesterol permits the influx of bicarbonate and Ca2+ ions, which in 
turn activate adenylate cyclase, thereby elevating cAMP concentrations. The 
increased cAMP levels activate protein kinase A, which then phosphorylates several 
tyrosine kinases, including chaperone proteins and those important for the 
acrosome reaction. These migrate to the sperm head where they are 
phosphorylated (Aitken and Nixon, 2013, Yoshida et al., 2008).  
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Hyperactivated sperm penetrate a layer of cells surrounding the oocyte (the cumulus 
oophorous) and undergo the acrosome reaction (Jin et al, 2011). The sperm then 
penetrate the zona pellucida enabling sperm-oocyte fusion and the completion of 
fertilisation.   
1.4.4 Sperm parameters  
 
Sperm motility is an easy measure of function and one of the most vital 
parameters, motile sperm are required for fertilisation otherwise the sperm cannot 
fertilise the oocyte.  
Human sperm motility is categorised into progressive (A+B), where the sperm are 
moving linearly or in large circles, non-progressive (C), sperm displaying any other 
patterns of motility and immotile (D), no movement whatsoever (World Health 
Organization, 2010a). When using computer assisted sperm analysis (CASA) 
progressive motility can be separated into fast progressive (A) (> 25 µm/sec) and 
slow progressive (B) (Figure 6). 
 
Figure 6. Sperm motility groups. A – fast progressive sperm, moves linearly or in large circles 
quicker than 25 µm/sec. B – slow progressive sperm, moves linearly or in large circles slower than 
25 µm/sec. C – non-progressive sperm, moves in small circles or ‘twitches’. D – immotile sperm, no 
movement. 
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1.4.5 Sperm chemotaxis  
 
Human sperm have been shown to respond to chemotactic factors in human 
follicular fluid (Ralt et al., 1994). In rabbits, progesterone has been identified as a 
chemotactic factor and is released from the oocyte-cumulus complex. Progesterone 
forms a concentration gradient as it diffuses away from the oocyte-cumulus 
complex. The sperm swim towards the more concentrated chemoattractant gradient 
(Guidobaldi et al., 2008). It has been observed that sperm chemotactic 
responsiveness is acquired during capacitation and it has been postulated that this 
is a means of selecting for capacitated sperm only (Cohen-Dayag et al., 1995). 
The role of neuropeptides in modulating sperm behaviour has not been explored in 
depth. It can be postulated that female stress and mood may influence post-coital 
fertility by altering sperm function. Furthermore, as neuropeptides have been 
detected in follicular fluid and semen they are likely to play an essential role in sperm 
physiology in both the male and female reproductive tracts (Figure 7).  
 
 
Figure 7. Neuropeptides on human fertility. Proposed hypothesis of the effects that 
neuropeptides may have on sperm and fertility. 
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1.5 Aims and Objectives 
 
Aim:   
(i) To investigate the presence of oxytocin, vasopressin and prolactin receptors on 
human sperm. 
(ii) To examine the function of oxytocin, vasopressin receptors on sperm through in 
vitro assays measuring intracellular responses to oxytocin, vasopressin treatment.  
  
Objectives: to investigate potential links between neuropeptides and sperm function 
via the following specific objectives: 
(i) Human sperm obtained from volunteers will be treated with oxytocin, 
vasopressin and prolactin 
(ii) Modulations in sperm motility will be assessed via CASA 
(iii) Immunolocation of neuropeptide receptors on human sperm.  
(iv) Cell signalling regulation after neuropeptide treatment will be 
investigated.  
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2.0 Materials and Methods 
 
Materials Used: 
 
Table 1. Equipment used. 
Equipment 
 
Agilent Technologies SureCycler 8800 – Thermal cycler 
Atto AE-6220 Duel Slab Chamber – SDS-PAGE gel tank 
Bio-Rad ChemiDocTM Touch Imaging System – Western blot and agarose gel 
imaging system 
Bio-Rad PowerPacTM Basic Power Supply - power supply for gel tanks and 
transfer system 
Bio-Rad Sub-Cell® GT Cell – Agarose gel electrophoresis tank 
Bio-Rad Trans-Blot® SD Semi-Dry Transfer System – Western blot transfer 
system  
BioTek® SYNERGY HT Microplate Reader 
 Leica DFC 365 FX – Fluorescent microscope 
Millipore Amplicon® Ultra 0.5ml centrifugal filters Ultracel® 3K – Protein 
concentration filters 
NUAIRETM Autoflow Direct Heat CO2 Incubator – Cell culture incubator 
NUAIRETM Biological Safety Cabinets – Class II safety cabinet 
Olympus CX41 – Phase contrast microscope (CASA) 
Scarstedt Falcon Tubes 
Sigma 3-16PK centrifuge 
SLS lab basics vortexer 
TECHNE Dri-Block® DB-2D – Heat block 
Thermo scientific NanoDrop 2000c Spectrophotometer 
Thermofisher Glassware 
Tomy Capsulefuge PMC-860  - Micro centrifuge 
Zeiss Axio Imager Z1 – Fluorescent microscope 
Gilson Pipettes  
Plasticware from Starstedt or Fisher Scientific 
Microplates – Grenia 
Cell culture plates and T75 Flasks – Nunc by Fisher Scientific 
Eppendorf tubes – Starlabs 
Pipette tips – Starlabs 
Sample collection pots – Sterilin UK 
CASA counting chamber 20 micron – Cell Vision 
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Table 2. Software used. 
Software 
 
AxioVision version 4.8.2.0 
Bio-Rad Image LabTM software 
Gen 5 version 2.05.5 BioTek® 
Microsoft® Excel® 2013 version (15.0.4841.1000) 
Sperminator® Pro Creative Diagnostics 1.0 
Leica LAS X Suite microscope imaging software 
 
 
Table 3. Antibodies used. 
Antibodies Supplier Catalogue # 
   
Alexa fluor® 488 F(ab') 2 goat anti-
mouse IgG, IgM (H+L) 
Thermo Fisher 
Scientific A-10684 
Alexa fluor® 488 goat anti-rabbit IgG 
(H+L) Invitrogen A-11008 
Anti-goat HRP Sigma A5420 
Anti-goat IgG-FITC 
Santa cruz 
biotechnology  
Anti-oxytocin receptor Abcam ab87312 
Anti-oxytocin receptor Abcam ab115664 
Anti-prolactin receptor Abcam ab2773 
Goat anti-rabbit HRP Bio-Rad 170-6515 
Monoclonal Anti-β-Tubulin antibody 
produced in mouse Sigma T4026 
Phospho(Ser/Thr) PKA substrate 
antibody Cell signalling 9621S 
Anti-AVPR V2 antibody Abcam Ab188748 
Primers Invitrogen A15612 
 
 
Table 4. Reagents used. 
Reagents Supplier Catalogue # 
   
[Arg8] Vasopressin acetate salt Sigma V9879 
2-Mercaptoethanol Sigma M7154 
5x DNA Loading Buffer Blue Bioline BIO-37045 
8-bromo-cAMP Abcam ab141448 
Acrylamide/Bis 30% solution Bio-Rad 161-0158 
Agarose Fisher scientific M-12198 
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AmershamTM Protran® Western 
blotting membranes, nitrocellulose AmershamTM GE10600001 
Ammonium persulphate Sigma A3678 
Bovine serum albumin Sigma A2153 
Bromophenol blue Sigma B8026 
Chloroform Sigma C7559 
DAPI Sigma D9542 
Dulbecco's Modified Eagle's Medium - 
high glucose Sigma D1145 
Ethanol Sigma 51976 
EZ-ECL Biological industries 20-500-120 
Foetal bovine serum Sigma F0804 
Glycerol Sigma G5516 
Glycine Sigma G8898 
GoTaq® 2-step RT-qPCR system Promega A6010 
Hydrochloric acid Sigma H1758 
HyperLadderTM 25bp Bioline BIO-33057 
HyperLadderTM 50bp Bioline BIO-33054 
ImmEdge Hydrophobic Barrier Pen 
(PAP pen) Vector H-4000 
Isopropanol Sigma I9516 
L-Glutamine Sigma G5792 
MagicMarkTM XP western protein 
standard Life technologies LC5603 
Marvel dried milk powder Sainsbury's 2051857 
Methanol Sigma 494437 
MyTaqTM DNA Polymerase Bioline BIO-21105 
N,N,N',N'-Tetramethylethylenediamine Sigma T9281 
Normal goat serum Vector S-1000 
Penicillin-Streptomycin Sigma P4333 
Phosphate Buffered Saline Oxoid BR0014G 
Phosphotase inhibitor cocktail set III Millipore 524627 
Pierce® BCA protein assay kit Pierce 23225 
Ponceau S Sigma P3504 
Precision plus proteinTM standards Bio-Rad 161-0376 
Protease inhibitor cocktail Sigma P8340 
Bicarbonate Sigma S3817 
Sodium chloride Sigma S3014 
Sodium deoxycholate Sigma S1827 
Sodium dodecyl sulphate Sigma L3771 
Sperm freezing medium Origio 10670010A 
Sperm preparation medium with 
Phenol Red Origio 10705060A 
SupraSperm® System Origio 10922060A 
Tris base Fisher scientific BP152-1 
TritonTM X-100 Sigma T8787 
TRIzol® Reagent 
Ambion life 
technologies 15596018 
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Trypsin Sigma T2600000 
Tween® 20 Sigma P9416 
Vectashield® mounting medium for 
fluorescence with DAPI Vector H-1200 
Whatman® gel blotting papers Whatman® WHA10426981 
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Methods 
[Note: further recipes in Appendix] 
2.1 Sample procurement 
 
Semen samples were produced by masturbation after 2-5 days of abstinence from 
healthy donors aged 18-38 years old (n = 5). Donors were given a participant 
information sheet with details of the study and completed a medical screening form 
and consent form, full ethical approval (see appendix 2). Semen was produced on 
site in a designated room and participants were instructed how to produce the 
sample in to a sample collection pot. 
All semen samples were assessed according to the WHO 5th edition (2010). 
Liquefaction of semen was carried out a 37°C, which was followed by measurement 
of semen volume, sperm concentration and motility assessment.  
To assess sperm motility and concentration, 5 µl of sample was applied to a 
counting slid and analysed using computer assisted sperm analysis (CASA) 
(Sperminator®) (Olympus CX41). The CASA measures sperm concentration 
(million/ml), velocity and grades sperm into A (fast progressive), B (slow 
progressive), C (non-progressive) and D (immotile) providing a percentage of these 
grades as an output (Figure 6).  
 
2.2 Sperm Isolation  
Sperm was separated from seminal plasma using density gradient centrifugation 
unless indicated otherwise, where the swim-up technique was employed.  
 
2.2.1 Density Gradient 
 
Sperm cells were separated from seminal plasma via density gradient 
centrifugation. Semen (1 ml) was layered on top of SupraSperm® gradient (55% - 2 
ml and 80% - 2 ml) and centrifuged at 300G for 20 minutes (Figure 8). Supernatant 
was discarded, 3 ml of sperm preparation media (SPM) was added and the pellet 
was resuspended. The sample was centrifuged at 300G for 10 minutes twice, 
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removing the supernatant each time. The remaining pellet was resuspended in 1 ml 
SPM, and the concentration and motility of sperm measured. 
 
Figure 8. Density gradient. 
 
2.2.2 Swim-Up Method 
 
For assessing PKA activity in sperm, the swim–up technique was used so minimise 
spontaneous capacitation in vitro. Sperm was placed beneath 2 ml of PBS and 
incubated at an angle of approximately 45° at 37°C for 30-60 minutes (Figure 9). 
Top layer of PBS was then pipetted into a falcon tube and washed with 3 ml PBS 
and pelleted via centrifugation at 300G twice. Pellet was resuspended in PBS (World 
Health Organization, 2010). 
 
Figure 9. Swim-up method. 
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2.3 Immunocytochemistry 
 
2.3.1 Fixing sample on slides 
 
The sample (10 µl) was smeared onto a slide. The slide was immersed in ice-cold 
methanol, 4% formaldehyde or 10% neutral buffered formalin (appendix 1) for 10 
minutes. The slide was air-dried and either used immediately or stored at -20°C until 
required. 
2.3.2 Immunolocalisation of neuropeptide receptors  
 
Slides taken from -20°C were left to thaw at room temperature for five minutes. The 
perimeter of the slides were drawn around with a PAP pen then rehydrated in 
phosphate-buffered saline (PBS) for 10 minutes and permeabilised in PBS-Tween 
0.1% (v/v) for 10 minutes. Blocking buffer [500 µl] was added to each slide, which 
was covered with the lid of the humidity chamber and left for 1 hour. Slides were 
washed in PBS-Tween 0.1% 3 times for 5 minutes (appendix 1). 
Primary antibody was diluted in blocking buffer (1:50, 1:100, 1:200) where 200 µl 
was added to the slides followed by overnight incubation at 4°C. A no primary 
antibody control was prepared by adding 200 µl of blocking buffer to a slide and 
stored as above.  
After incubation, all slides were washed in PBS-Tween 0.1% 3 times for five 
minutes. At low light levels, 250 µl of the appropriate fluorescent-conjugated 
secondary antibody (1:2000 dilution with blocking buffer unless otherwise stated) 
was added to each slide. Slides were covered and left for 1 hour. Slides were 
washed 3 times in PBS-Tween 0.1% for five minutes in darkness. A drop of 
VECTASHIELD® mounting medium with DAPI was added to each slide, a coverslip 
was placed on top and sealed with an enamel sealant. Slides were left in darkness 
for half an hour to develop before imaging using fluorescent microscopy (Zeiss Axio 
Imager Z1/Leica DFC 365 FX). 
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2.4 Cell culture and in vitro assays.  
 
All cells were cultured in class II safety cabinets and incubated in direct heat 5% 
CO2 incubators at 37°C. 
All cells, excluding sperm, were cultured using standard culture media (appendix 1) 
and standard cell culture technique in either 6 well cell culture plates or T75 flasks. 
Sperm cells were prepared via density gradient/swim-up and washed twice in sperm 
preparation media (SPM), SPM was the media used in all experiments unless 
otherwise specified.  
 
2.4.1 Incubations with agonists 
 
All cells were incubated with neuropeptide (10 pM, 10 nM, 10 µM) or positive control 
8-bromo-cAMP (100 µM) agonists in their appropriate media, either SPM or 
standard culture media (appendix 1), at 37°C for 5-90 minutes. 
 
2.5 Protein extraction and quantification 
 
2.5.1 Radioimmunoprecipitation assay cell/tissue lysis  
  
Radioimmunoprecipitation assay (RIPA) lysis buffer (appendix 1) was used for 
protein extraction (Six and Kasel, 1978). 1 ml of RIPA with 1:100 (v/v) protease 
inhibitor cocktail and 1:100 (v/v) phosphotase inhibitor cocktail was used for 10 
million cells or 0.1 g of tissue. Sample and lysis buffer were incubated at 4°C under 
constant agitation for 30-60 minutes dependant on whether it was cells (30 minutes) 
or tissue (60 minutes). 
Samples were centrifuged at 12,000G for 20 minutes at 4°C, the supernatant was 
aspirated and stored at -80°C and the pellet discarded.  
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2.5.2 Protein quantification – Bicinchonic acid assay (BCA assay) 
 
Bicinchonic acid (BCA) assay was used (Pierce™ BCA protein assay kit) to quantify 
all proteins. The BCA assay is a colourmetric assay that determines total protein 
concentration due to colour changes in the samples when compared to known 
standards (Smith et al., 1985). Protein standards were made to the manufacturer’s 
instructions. Reagent A was mixed with reagent B at 50:1 (v/v) to make the working 
reagent, 25 µl of protein standard or sample was pipetted into a 96 well microplate 
and 200 µl of working reagent was added to each protein sample. The microplate 
was incubated at 37°C for 30 minutes and then absorbance was measured at 562 
nm on a microplate reader. Standard curve was calculated using Microsoft® Excel 
software and equation from graph (y=mx+c) was used to quantify unknown proteins. 
 
2.6 Western blotting 
 
2.6.1 SDS-Page 
 
Table 5. SDS-Page gel recipe. 
Reagent Separating Gel Stacking Gel 
dH2O 3.2 ml 5.6 ml 
Separating buffer 2.5 ml - 
Stacking buffer - 2.5 ml 
Bis/Acrylamide 30% 4.3 ml 1.9 ml 
APS 10% 100 µl 100µl 
TEMED (add last) 10 µl 10 µl 
 
Separating gel was prepared in a universal tube as per recipe in Table 5. Of the 
separating gel, 5 ml was pipetted into the gel cast, 100 µl of isopropanol was 
pipetted on top of the gel to ensure it sets evenly and the gel was left to polymerise 
for 15 minutes. The isopropanol was decanted and gel rinsed with dH2O. Stacking 
gel was prepared in a universal as per recipe in table 5, this was then pipetted on 
top of the separating gel until the gel cast was full, the gel comb was then inserted 
and the gel was left to polymerise for a further 15 minutes. Once the gel was set the 
gel casts were placed in the gel tank and it was filled with electrode buffer to the 
marker and gel combs removed.   
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Protein samples were diluted laemmli buffer 4X (appendix 1) and then heat 
denatured at 100°C for 15 minutes. 2.5 ng/µl of protein sample was loaded into the 
gel (unless otherwise stated) along with protein ladder at manufacturer’s 
recommendation. Gel tank was connected to power pack and ran at 60V for 60 
minutes, then the voltage was increased to 120V and left to run until the dye front 
reached the end of the gel. 
 
2.6.2 Blotting 
 
Stacking gel was removed and discarded. Blotting paper was cut into 8 pieces per 
gel and soaked in towbin buffer (appendix 1) along with the nitrocellulose membrane 
for approximately 2 minutes. A sandwich of 4 pieces of blotting paper, the 
nitrocellulose membrane, the gel and a further 4 pieces of blotting paper, in that 
order, were laid out onto the transfer system. Any air bubbles were eliminated from 
this ‘sandwich’ by rolling a clean test tube (or something similar) over the 
components. The lid was placed on the transfer system and connected to the power 
pack, this was then ran at 100V for 1 hour (unless otherwise stated). 
 
2.6.3 Blocking 
 
The membrane was then incubated for 1 hour in blocking buffer (5% bovine serum 
albumin in 0.01% TBS-T v/v, unless otherwise stated, appendix 1) at room 
temperature on a shaker. Blocking buffer was then discarded and primary antibody 
solution (1:1000 antibody to blocking buffer v/v) was added to membrane and the 
membrane was incubated overnight at 4°C on a shaker. 
Primary antibody was discarded and the membrane was washed for 5 minutes in 
triplicate with PBS-T at room temperature on a shaker. The appropriate secondary 
HRP conjugated antibody was then added in solution (1:1000 antibody to TBS-T 
v/v, unless otherwise stated) to the membrane and left to incubate on a shaker at 
room temperature. Secondary antibody solution was discarded and membrane was 
once again washed 3 times for 5 minutes with TBS-T at room temperature on a 
shaker.  
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2.6.4 Developing 
 
Membranes were kept in TBS-T to prevent them from dehydrating. Cling film was 
laid out on a flat surface and membrane was placed onto the cling film protein side 
up. Electrochemiluminescence (ECL) solution was used to develop the membrane. 
In the dark, ECL solution A and B were mixed in equal parts and then 1ml of ECL 
solution was added to the membrane and left to develop for approximately 5 
minutes. The ECL was drained off and the membrane was imaged using 
ChemiDocTM Touch Gel and Western Blot Imaging System. 
Membranes were then washed 3 times with TBS-T for five minutes and incubated 
with loading control antibody overnight at 4°C on a shaker and the process from 
then on was repeated. 
 
2.7 RNA extraction (Trizol & Chloroform) 
 
Suspension cells were pelleted via centrifugation at 300G for 10 minutes and the 
supernatant removed prior to extraction.  RNA was extracted from adherent cells 
directly from the cell culture flask as follows; culture media was removed and the 
TRIzol® reagent was added at the appropriate volume for the amount of cells, 
usually either 1 or 2 ml (usually 1 ml for sperm, 2 ml for HeLa/other adherent cells 
in a T75 flask) and left for 15 minutes at room temperature. TRIzol® reagent was 
added. The TRIzol® cell suspension was transferred to 1.5 ml Eppendorf tubes (as 
many as appropriate) and 200 µl of chloroform was added to each Eppendorf tubes 
and vigorously shaken. These were then left for a further 15 minutes at room 
temperature. The Eppendorf tubes were centrifuged at 12,000G for 15 minutes at 
4°C. The aqueous phase, which is clear and containing the RNA, was pipetted into 
a new 1.5 ml Eppendorf tubes and 500 µl of isopropanol was added. This was then 
vortexed and left at room temperature for 10 minutes. The suspension was 
centrifuged at 12,000G for 10 minutes at 4°C and the supernatant was aspirated 
and discarded. After, 1 ml of 75% ethanol was added, vortexed and centrifuged at 
8000G for 5 minutes at 4°C. The supernatant was aspirated and discarded and the 
pellet was dissolved in 30 µl of nuclease free water. RNA quantity and purity was 
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investigated using NanoDrop 2000C Spectrophotometer. After quantification RNA 
was immediately reverse transcribed into cDNA to avoid degradation during storage, 
any remainder of RNA was stored at -80°C for up to 6 months. 
 
2.8 Polymerase Chain Reaction (PCR) 
 
2.8.1 Primer design  
 
All primers were designed using Primer3 Plus hosted by NCBI for use with BLAST. 
 
2.8.2 Reverse transcription PCR: 
 
All reverse transcription was performed using Agilent’s SureCycler 8800 thermal 
cycler and a reverse transcription kit (GoTaq® 2-Step RT-qPCR System by 
Promega). Following manufacturer’s instructions, on ice, RNA and reverse 
transcription primer was combined appropriately using up to a maximum of 5 μg 
per reaction and to a final volume of 10 μl. This mixture was denatured at 70°C for 
5 minutes and chilled at 4°C for 5 minutes. The GoScriptTM reaction mix was 
prepared as follows, Nuclease-Free Water - 1.5 µl, GoScript™ 5X Reaction Buffer 
– 4 µl, MgCl2 25 mM – 2 µl, PCR Nucleotide Mix 10 mM – 1 µl, Recombinant 
RNasin® Ribonuclease Inhibitor  - 0.5 µl, GoScript™ Reverse Transcriptase – 1 
µl. The reaction mix was combined with the RNA and reverse transcription primer 
in the reaction tube and cDNA was synthesised under the following cycle 
conditions: 
Table 6. cDNA synthesis cycle conditions for GoTaq 2-Step RT-qPCR system by Promega. 
Step Temperature Time 
Anneal 25°C 5 minutes 
Extend 42°C 1 hour 
Inactivate 70°C 15 minutes 
cDNA was stored at -20°C until use. 
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2.8.3 Endpoint PCR 
 
Primers were optimised using a thermal cycler and a DNA polymerase kit. Following 
the manufacturer’s instructions, on ice, in the reaction tube the reaction was set up 
as follows: 
5x MyTaq Reaction Buffer – 10 µl  
cDNA - as required  
Primers 20 µM each – 1 µl  
MyTaq DNA Polymerase – 1 µl  
ddH2O - up to 50 µl 
 
The following cycling conditions were used to amplify the target: 
Table 7. Endpoint PCR cycle conditions for primer optimisation. 
Step Temperature Time 
Initial 
denaturation 
95°C 1 minute 
Denaturation 95°C 30 seconds 
Annealing 60°C 30 seconds 
Extension 72°C 30 seconds 
 
x35 cycles 
 
Final Extension 72°C 10 seconds 
 
PCR product was immediately used in agarose gel electrophoresis to ensure 
appropriate amplification of the target sequence (Table 6). 
 
2.8.4 Agarose Gel Electrophoresis  
 
All gels were composed of 2% agarose in 1X TBE buffer (appendix 1) with midori 
green as the DNA intercalating agent. Bioline 5x DNA loading buffer blue was mixed 
appropriately with the PCR product prior to loading, Bioline HyperLadderTM 25bp or 
50bp were used appropriately dependant on expected amplicon size and the gel ran 
at 80V for 60 minutes, or until the dye front reached the end of the gel. 
Gels were imaged using ChemiDocTM Touch Gel and Western Blot Imaging System. 
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2.9 Statistical analysis 
 
Statistical analysis of progressive sperm motility was performed in Microsoft 
Excel® 2013 software using a standard paired T-Test. Analysis of western blot 
band intensity was performed in Bio-Rad Image LabTM software. 
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3.0 Results 
 
3.1 Immunolocalisation of neuropeptide receptors on human sperm 
 
Immunocytochemistry was employed to investigate the presence of neuropeptides 
receptors on sperm cells. Sperm separated from seminal plasma was fixed on slides 
and probed for vasopressin receptor 2, oxytocin receptor and prolactin receptor. 
 
 3.1.1 Immunolocalisation of vasopressin receptor 2  
 
Human kidney cells (HK2) express the vasopressin receptor 2 (Thibonnier et al., 
1998) and was used as a positive control for vasopressin receptor 2 
immunolocalisation showing positive cell surface staining of the receptor in all cells 
(Figure 10).  
 
 
Figure 10. Immunolocalisation of vasopressin receptor 2 on human kidney cells 
(HK2). HK2 cells stained for vasopressin receptor 2 (green) localized on the cell surface 
membrane (A). No primary antibody control (B). Nuclei were stained with DAPI (blue). 
Magnification x640. Representative images from N = 3. 
Immunolocalisation of vasopressin receptor 2 displayed strong staining on the 
acrosome region of human sperm, staining was seen on most sperm cells however 
a few did not show staining for the vasopressin receptor 2 and it is postulated that 
this is due to its localisation on the acrosome, some sperm may have undergone 
spontaneous acrosome reaction and therefore no longer have the receptor present 
(Figure 11).  
A                                                                            B 
29 
 
 
Figure 11. Immunolocalisation of vasopressin receptor 2 in human sperm. 
Vasopressin receptor 2 (green) was localized to the acrosome region of sperm (A and 
insert). No primary antibody control (B). Nuclei were stained with DAPI (blue). 
Magnification x1000. Representative images from N = 5. 
 
3.1.2 Immunolocalisation of oxytocin receptor 
 
MCF-7 cells, a human breast cancer cell line known to express the oxytocin receptor 
(Cassoni et al., 1994), was used as a positive control.  Positive staining for oxytocin 
receptor on the cell surface membrane on all cells is shown in Figure 12.  
No immunolocalisation of oxytocin receptor was detected on human sperm (Figure 
13). 
 
 
Figure 12. Immunolocalisation of oxytocin receptor in MCF-7 cells (human breast 
cancer cell line). MCF-7 cells stained for oxytocin receptor (green) localized on the cell 
surface membrane (A). No primary antibody control (B). Nuclei were stained with DAPI 
(blue). Magnification x400. Representative images from N = 3. 
 
 
A B 
A                                                                         B 
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Figure 13. Immunolocalisation of oxytocin receptor in human sperm. Oxytocin 
receptor was not detected on human sperm (A). No primary antibody control (B). Nuclei 
were stained with DAPI (blue). Magnification x400. Representative images from N = 3. 
 
3.1.3 Immunolocalisation of prolactin receptor 
 
MCF-7 express prolactin receptors (Melck et al., 2000) and were used as a positive 
control in these studies. Immunolocalisation with clear labelling observed on the cell 
surface of each cell (Figure 14). However, prolactin receptor was not detected on 
human sperm in the present study (Figure 15). 
 
 
Figure 14. Immunolocalisation of prolactin receptor in MCF-7 cells. MCF-7 cells 
stained for prolactin receptor (green) localized on the cell surface membrane (A). No 
primary antibody control (B). Nuclei were stained with DAPI (blue). Magnification x400. 
Representative images from N = 3. 
 
A                                                                           B 
A                                                                            B 
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Figure 15. Immunolocalisation of prolactin receptor in human sperm. Prolactin 
receptor was not detected on human sperm (A). No primary antibody control (B). Nuclei 
were stained with DAPI (blue). Magnification x400. Representative images from N = 3. 
 
3.2 Neuropeptides and sperm function  
 
This study has localised vasopressin receptor 2 on human sperm. However,  
oxytocin and prolactin were not localised on sperm, therefore the role of vasopressin 
on human sperm was further investigated.  
 
3.2.1 Vasopressin and sperm motility  
 
Human sperm were separated from seminal plasma using density gradient 
centrifugation (as outlined in section 2). Washed sperm were incubated with 
vasopressin agonist at concentrations (10 pM, 10 nM and 10 µM) for 30 and 90 
minutes at 37°C.  Sperm motility was measured using on the CASA. Progressive 
motility was calculated by adding motility grade A and B (WHO, 2010). No significant 
difference was observed between the control and treatment progressive motility 
after incubation with vasopressin (Figures 14 and 15) [statistical analysis: 2-tailed, paired 
t-test p = > 0.05. N = 4].  
 
 
A                                                                             B 
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Figure 16. Percentage progressive motility after 30 minutes 
incubation with vasopressin at varying concentrations and no 
treatment control. No difference in percentage progressive motility was 
observed at any concentration, statistical analysis (p = > 0.05. N = 4.) 
 
 
Figure 17. Percentage progressive motility after 90 minutes 
incubation with vasopressin at varying concentrations and no 
treatment control. No difference in percentage progressive motility was 
observed at any concentration (p = > 0.05. N = 4). 
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3.3 PKA activation  
 
To further investigate the effects of vasopressin on the cellular function of human 
sperm, the activation of PKA was examined through immunolocalisation of 
phosphorylated serine and threonine substrates using the phospho-PKA substrates 
antibody. These substrates are phosphorylated by PKA and can be used as a 
measure of PKA activity within the cell (Kwon et al., 2013).  
There were no visible signal differences between all treatments and controls 
(Figures 18, 19, 20, 21 and 23) except for the sperm cells incubated with the PKA 
activator 8-bromo-cAMP. PKA was localised in HeLa throughout the cell (Figures 18 
and 19), in sperm it was localised to the tail except when incubated with 8-bromo-
cAMP in which there was also localisation on the equatorial region of the head of 
the sperm (Figure 22 and arrow in A). 
 
3.3.1 Phospho-PKA substrates immunocytochemistry 
 
As a positive control and for assay optimisation HeLa cells were utilised. HeLa were 
treated with PKA activator 8-bromo-cAMP and immunolocalisation of  phospho-PKA 
substrates in HeLa cells with and without treatment positive staining for phospho-
PKA substrates evenly throughout the cells and in all cells with no visible signal 
differences between the two samples (Figures 18 and 19).  
 
 
Figure 18. Immunolocalisation of Phospho-PKA Substrates in HeLa cells induced with 8-
bromo-cAMP. Phospho-PKA substrates (green) detected on HeLa cells induced with 8-Bromo-
cAMP (A). No primary antibody control (B). Nuclei were stained with DAPI (blue). Magnification x400. 
Representative images from N = 3. 
B A 
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Figure 19. Immunolocalisation of Phospho-PKA Substrates in HeLa cells. Phospho PKA 
substrates (green) detected on HeLa cells (A). No primary antibody control (B). Nuclei were stained 
with DAPI (blue). Magnification x400. Representative images from N = 3. 
Immunolocalisation of phospho-PKA substrates in human sperm showed 
localisation primarily in the tail of the sperm (Figures 20, 21, 22, 23). All sperm 
samples were separated from the seminal plasma via swim-up method in PBS 
(methods section 2.2.2). In Figure 20, a no treatment control, positive staining for 
phospho-PKA substrates was observed on the tail of the sperm, no staining was 
observed elsewhere (Figure 20, A). In Figure 21 sperm were treated with 25mM 
bicarbonate to capacitate the sperm (Da Ros et al., 2004, Stauss et al., 1995). This 
was done as sperm that have undergone capacitation have been observed to have 
a much higher rate of PKA activity than non-capacitated sperm (Lefievre et al., 
2002). Localisation of phospho-PKA substrates was once again observed along the 
tail of the sperm (Figure 21, A). In Figure 22 sperm were treated with 100 μM of the 
PKA activator 8-bromo-cAMP for 5 minutes and showed increased signal 
differences for phospho-PKA substrates from the other treated and control samples, 
including positive staining for the phospho-PKA substrates along the equatorial 
region of the head of the sperm (Figure 22, A, arrow). This indicated that the PKA 
activator 8-bromo-cAMP could successfully be used to increase PKA activity in vitro. 
Figure 23 showed sperm incubated with 10 μM of vasopressin agonist, positive 
immunolocalisation of the phospho-PKA substrates was once again observed along 
the tail of the sperm (Figure 23, A).  
All no primary controls showed no staining indicating there was no non-specific 
binding of the antibody (C in Figures 20, 21, 22 and 23). 
Phase contrast images of both stained and no primary controls showed the full 
sperm morphology (B and D in Figures 20, 21, 22 and 23) 
B A 
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There were no visible signal differences for phospho-PKA substrates between the 
control, capacitated sperm and sperm incubated with vasopressin (Figure 20, A , 
Figure 21, A and Figure 23, A). 
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Figure 20. Immunolocalisation of Phospho-PKA Substrates in human sperm cells. Phospho PKA substrates 
(green) detected on human sperm washed and incubated with PBS (A). Phase contrast image of A (B). No primary 
control (C) and phase contrast of no primary control (D). Nuclei were stained with DAPI (blue). Magnification x400. 
Representative images from N = 1. 
A B 
C D 
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Figure 21. Detection of Phospho-PKA Substrates in capacitated human sperm cells. Phospho-PKA substrates 
(green) detected on human sperm washed in PBS and incubated with 25mM HCO3. (A). Phase contrast image of A (B). 
No primary control (C) and phase contrast of no primary control (D). Nuclei were stained with DAPI (blue). Magnification 
x400. Representative images from N = 1. 
D C 
B A 
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Figure 22. Detection of Phospho-PKA Substrates in human sperm cells washed in PBS and incubated with 8-
Bromo-cAMP. Phospho-PKA substrates (green) detected on human sperm washed in PBS and incubated with 8-
Bromo-cAMP. (A). Phase contrast image of A (B). No primary control (C) and phase contrast of no primary control (D). 
Nuclei were stained with DAPI (blue). Magnification x400. Representative images from N = 1. 
D C 
B A 
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Figure 23. Detection of Phospho-PKA Substrates in human sperm cells washed in PBS and incubated with 10µM 
vasopressin. Phospho-PKA substrates (green) detected on human sperm washed in PBS and incubated with 10µM 
vasopressin. (A). Phase contrast image of A (B). No primary control (C) and phase contrast of no primary control (D). 
Nuclei were stained with DAPI (blue). Magnification x400. Representative images from N = 1. 
D 
B A 
C 
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3.3.2 Phospho PKA substrates western blots 
 
To investigate the regulation of PKA, HeLa and sperm cells were incubated with 8-
bromo-cAMP to induce PKA phosphorylation activity as a positive control for PKA 
phosphorylation activity.  
Western blot analysis for phospho-PKA substrates showed, in HeLa, the PKA 
activator 8-bromo-cAMP upregulated phospho-PKA activity after both 5 and 30 
minutes in bands at 25 kDa and 30 kDa when corrected for Actin using Image LabTM 
software. No observable difference between the 5 and 30 minute incubations with 
8-bromo-cAMP (Figures 24a and 24b). Western blots using sperm did not show any 
conclusive data, which may be due to poor protein yields from the human sperm 
samples. Further optimisation is required in order to obtain results from sperm 
samples (Figure 25). 
 
 
 
Figure 24. Overlay of representative western blot of Phospho-PKA substrates 
and Actin protein extracted from untreated and treated HeLa cells. HeLa cells 
were untreated (HeLa C) and treated with 8-bromo-cAMP for 5 minutes (HeLa 5) 
and 30 minutes (HeLa 30). Representative images from N = 9. 
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Figure 24b. Band intensity ratio for band A and band B of representative western 
blot 24a. HeLa Actin band compared to HeLa band A and B treated for 5 minutes with 
PKA activator 8-bromo-cAMP (HeLa 5) and treated for 30 minutes with PKA activator 8-
bromo-cAMP (HeLa 30). Representative of N = 1. 
 
 
Figure 25. Overlay of representative western blot of Phopho PKA substrates and 
β-Tubulin protein extracted from untreated and treated human sperm cells. Human 
sperm were washed and untreated (Sperm C) and treated with vasopressin for 5 minutes 
(sperm VP) and for 5 minutes PKA activator 8-bromo-cAMP (sperm 8-bromo-cAMP). 
Representative images from N = 1.  
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3.4 Exploring Neuropeptide transcripts in human sperm.  
To further investigate the presence of neuropeptide receptors in human sperm 
transcripts for vasopressin receptor 2, prolactin receptor and oxytocin receptor were 
explored.  
Sperm cells are transcriptionally quiescent (Johnson et al., 2011), however the 
neuropeptide receptor transcripts may be present in mature sperm (carried on from 
spermatids and earlier cells from spermatogenesis) regardless of whether the 
receptor itself is present on mature human sperm. Should the transcripts be present 
this could indicate a possible role during spermatogenesis and sperm maturation 
that may be vital for mature sperm function. Oxytocin receptor primers 2,3 and 5 
were optimized using cDNA from MCF-7 cells (appendix 3). However, for sperm 
samples optimization was not yet possible during this study and further work is 
required.  
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4.0 Discussion  
 
This study set out to investigate the role of neuropeptides on human sperm, by 
localising the receptors on human sperm and examining of any physiological role.   
The oxytocin and vasopressin receptors have been found throughout both male and 
female reproductive tissues, the epididymis, vas deferens, leydig cells, prostate, 
testis (Filippi et al., 2002) and the ovaries (Fuchs et al., 1990). Vasopressin, oxytocin 
and prolactin are found in both seminal plasma and follicular fluid (Brotherton, 1990; 
Schaeffer et al., 1984; Goverde et al., 1998; Laufer et al., 1984; Schoenfeld et al., 
1979) indicating a possible role in sperm function and fertilisation. 
In the present study, the vasopressin receptor 2 was immunolocalised on the 
acrosome region of the human sperm (Figure 11). However, both the oxytocin and 
prolactin receptors were not immunolocalised (Figures 13 and 15).  
To date, the oxytocin receptor has not been localised on sperm. Oxytocin, in high 
levels, is known to have an affinity for the vasopressin receptor 2 (Joo et al., 2004, 
Li et al., 2008). Though the oxytocin was not localised in human sperm, in high 
levels, oxytocin may function through the vasopressin receptor 2 on sperm. Kwon 
et al. (2013) showed that when the vasopressin receptor 2 is activated in sperm it 
has negative effects on sperm function (motility, capacitation and acrosome 
reaction). One study showed that the use of an oxytocin antagonist improved the 
fertility of a woman who suffered 15 years of infertility and 7 failed in vitro 
fertilisation/embryo transfer attempts (Pierzynski et al., 2007). Oxytocin is known to 
be present in high levels in pregnant and breastfeeding women (Kumaresan et al., 
1974; Nissen et al., 1996; Otsuki et al., 1983; Uvnäs-Moberg et al., 1990). It could 
therefore be postulated that oxytocin at high levels may modulate sperm function 
locally in the tubal milieu. 
In this study the prolactin receptor was not localised on human sperm, however 
Pujianto et al. (2010) showed expression of the prolactin receptor on human sperm 
in particular in the tail region. They demonstrated that prolactin has prosurvival 
effects on human sperm via the inhibition of apoptosis, supports prolonged motility, 
suppresses capacitation and prevents the formation of spontaneous DNA 
fragmentation via caspase suppression.  
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Vasopressin receptor 2 was the only neuropeptide receptor localised on human 
sperm in this study. Therefore, the role of vasopressin in sperm function was further 
investigated. An easy and effective measure of function is progressive sperm 
motility. Motile sperm is vital for fertilisation to occur and easy to measure in vitro 
either manually or using CASA. Capacitation causes sperm to be hypermotile, an 
influx of intracellular calcium leads to an upregulation of PKA, all essential for 
acrosome reaction and fertilisation. Should time have permitted this study would 
have benefitted from investigating capacitation status and acrosome reaction in 
order to have a more complete idea of any effect that vasopressin may be having 
on human sperm function. Sperm incubated at various concentrations of 
vasopressin for 30 and 60 minutes showed no significant difference in motility 
between control and treated samples (Figures 16 and 17). However, Kwon et al. 
(2013) found in mouse sperm there was a dose dependant negative effect on 
percentage progressive sperm motility when incubated with vasopressin, but only a 
significant difference at the highest concentration (10 µM). They found that high 
quantities of vasopressin strongly inhibited the acrosome reaction and capacitation 
and suggested that vasopressin has strong negative effects on normal sperm 
function and the potential use of vasopressin as a male contraception. If the 
vasopressin receptor 2 has inhibitory effects on sperm function and high levels of 
vasopressin are present in the Fallopian tube during acute stress, sperm may be 
negatively affected therefore lowering fertility. This could be a method of post-coital 
sexual selection, whereby females may influence the behaviour of sperm locally 
through increasing levels of vasopressin during times of duress (Nakanishi et al., 
2004; Sakkas et al., 2015). 
The findings of Kwon et al. (2013) and the present study have revealed some 
differences in the localisation of the vasopressin receptor 2 on sperm. In mouse, the 
receptor was localised along the tail and midpiece. Furthermore, Kwon et al. (2013) 
used sperm from the caput epididymis, which are not mature and do not have the 
ability to be motile or fertilise an oocyte (Jones, 1999). They also used sperm 
isolated from the cauda epididymis and showed localisation on the acrosome, 
indicating that the vasopressin receptor 2 develops on the acrosome during sperm 
maturation (Kwon et al., 2013). In the present study, mature human sperm produced 
via masturbation and the vasopressin receptor 2 was localised exclusively on the 
acrosomal region (Figure 11). Further investigation into immunolocalising the 
45 
 
vasopressin receptor 2 on immature human sperm would support the idea that the 
vasopressin receptor 2 develops on sperm during maturation. 
No significant effect on human sperm progressive motility was observed after 
treatment with vasopressin, this could be due to the small sample size used in this 
study with limited donors and further investigation is required.  
To examine any intracellular signalling activity of vasopressin on sperm, the activity 
of PKA was analysed. The vasopressin receptor 2 is a G protein-coupled receptor 
(Gs alpha subunit) that activates the cAMP dependant pathway. The increases in 
cAMP which activates PKA, thus phosphorylating serine and threonine residues on 
target proteins (Neves et al., 2002).  
To optimise the assay, HeLa cells were used. After treatment with 8-bromo-cAMP  
with PKA activator and then probed for any PKA activity via immunocytochemistry. 
Both control and treated samples showed strong labelling for phospho-PKA 
substrates throughout the cell, though no visible difference in fluorescent signal was 
observed (Figures 18 and 19).  
PKA is activated during capacitation (Lefievre et al., 2002) and capacitation can be 
induced in vitro using bicarbonate. To induce sperm PKA activity in this study, sperm 
were treating with bicarbonate (25mM) (Da Ros et al., 2004; Lefievre et al., 2002) . 
The capacitated sperm showed positive labelling for phospho-PKA substrates along 
the tail (Figure 20) but no visible differences in fluorescence were observed between 
this and the control sample (Figure 20). This may be due to sperm undergoing 
spontaneous capacitation. 
The sperm sample incubated with PKA activator 8-bromo-cAMP showed positive 
staining for phospho-PKA substrates along the tail and the equatorial region of the 
head (Figure 22). There was an increased immunofluorescence in treated sperm 
compared to untreated sperm, which may indicate increased PKA activity. This 
showed that 8-bromo-cAMP induces increased phosphorylation of on target 
proteins via PKA in human sperm, allowing for its use as a positive control in further 
assays. 
After treatment with vasopressin, sperm showed positive staining for phospho-PKA 
substrates along the tail (Figure 23), though no visible difference in PKA activity was 
observed between the treated and control sample. Though it may not be a visible 
difference via immunofluorescence, Kwon et al. (2013) showed that vasopressin 
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decreases phospho-PKA substrates in sperm in a dose dependant manner via 
western blot analysis. 
To assess PKA activity cells were treated with PKA activator 8-bromo-cAMP. To 
optimise the assay – HeLa cells were used. Extracted protein was used for western 
blot analysis and probed for phospho-PKA substrates. HeLa cells treated with 8-
bromo-cAMP (after 5 and 30 minutes incubations) showed upregulation of PKA 
activity through increased phosphorylation of target proteins (Figures 24a). Further 
analysis showed upregulation of substrates phosphorylation around 25 and 30 kDa 
(Figures 24b). These data demonstrate that PKA activity can be detected after 
stimulation of cells in vitro using 8-bromo-cAMP. The next step was to examine PKA 
activity in sperm. Sperm were treated with 8-bromo-cAMP and vasopressin for 5 
minutes.  However, when western blotting was attempted with human sperm protein 
extract after treatment with 8-bromo-cAMP and vasopressin no conclusive data 
were obtained. This assay requires further optimisation and due to time restraints, 
this was not possible during this study. 
Although sperm are transcriptionally quiescent and the oxytocin and prolactin 
receptors may not be present on mature human sperm, if the transcripts are present 
this could indicate a role for the neuropeptide and its receptor earlier in 
spermatogenesis. Kwon et al. (2013) found when immunolocalising vasopressin 
receptor 2, the receptor was not present on the acrosome of the caput mouse sperm 
(immature) until the mouse sperm was further matured in the cauda. The presence 
of transcripts for neuropeptide receptors in sperm was explored.   
Primers for the human oxytocin receptor were optimised using cDNA from MCF-7 
cells, known to express oxytocin receptor. Oxytocin receptor primer sets 2, 3 and 5 
amplified as expected and the no template controls were clear (appendix 3). No 
conclusive data was generated for in the present study. 
 
4.1 Limitations and future work 
 
The major limitations of the present study were mostly technical, which include 
optimisation of Western blots and immunocytochemistry. Given the time scale of 
this study, it was not possible to acquire data that are more conclusive.  
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To further investigate the role of neuropeptides on sperm function, other 
neuropeptides that have been implicated in reproduction such as neuropeptide Y, 
leptin, PACAP, ghrelin and others (Brann et al., 2002; García et al., 2007; Shintani 
et al., 2002; Toufexis et al., 2002) should be explored via immunocytochemistry for 
their receptors in human sperm. If the receptor is successfully located to then 
explore any modulation in motility after incubation with a specific receptor agonist 
and antagonist.  
Using proteomics to fully profile any neuropeptides found in follicular fluid and 
semen would give direction to further exploration of neuropeptides involved in 
reproduction and potentially sperm function. Any chemotactic effects of these 
neuropeptides could be investigated via a simple assay using a microfluidic device 
(Koyama et al., 2006). 
As the vasopressin receptor 2 was localised on the acrosome region on the head of 
the human sperm in order to investigate the effects this receptor has when activated 
the experiments mentioned in this study require further optimisation and larger 
sample sizes in order to negate for both inherent differences in between donors and 
samples themselves. To further explore vasopressin’s effect on human sperm 
function both capacitation status and acrosome reaction post-incubation with 
vasopressin agonist and antagonist should be explored. Percentage of positively 
labelled sperm should be measured in order to obtain more quantitative data.  As 
the vasopressin receptor 2 is found on the acrosome this suggests that it may play 
a part in the acrosome reaction. In renal cells, the vasopressin receptor 2 triggers 
the signalling cascade, activating adenylyl cyclases, which activate cAMP, 
activating PKA resulting in the translocation of aquaporin 2 channels from the 
intracellular vesicle to the cell membrane (Dibas et al., 1998; Nielsen et al., 1995), 
aquaporin 2 has been localised in the ampulla of the vas deferens of the rat and is 
suggested that it is involved in sperm concentration via fluid removal from the lumen. 
However, the aquaporin 2 channels found in the vas deferens have been shown to 
not be regulated by vasopressin unlike in renal cells (Matsuzaki et al., 2002; Stevens 
et al., 2000). Vasopressin could potentially be important in the acrosomal shedding 
during acrosome reaction via increased osmosis via this pathway. 
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5.0 Conclusion  
 
The presence of the receptors for neuropeptides oxytocin, vasopressin and prolactin 
was explored. The vasopressin receptor 2 was the only receptor localised on human 
sperm and any functional role was examined though results were limited. Sperm 
exposed to varying concentrations of vasopressin in vitro did not show any effect on 
progressive sperm motility. Sperm PKA activation by vasopressin was investigated 
– however, no conclusive data was obtained.  
The vasopressin receptor 2 was localised to the acrosomal region.  It is therefore 
likely that vasopressin may play a role in the acrosome reaction. Further work is 
required to establish any role vasopressin has on human sperm. Additionally, 
investigating the possible roles of other neuropeptides and sperm function is an area 
worth investigating, linking neuroendocrinology and sperm biology.   
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7.0 Appendices 
1 
Recipes 
Western blotting recipes 
Separating buffer 
1 g SDS 
45.4 g Tris Base 
Make up to 250 ml with dH2O  
Adjust to pH 8.8 
Can be stored at room temperature for a few months 
 
Stacking Buffer 
1 g SDS 
15 g Tris Base 
Make up to 250 ml with dH2O 
Adjust to pH 6.8  
Can be stored at room temperature for a few months 
 
APS 
 
10% solution  
(e.g. 100 mg in 1 ml dH2O) 
Can be stored in the fridge for a week 
 
Running buffer/Electrode buffer 
 
12.02 g Tris Base 
4 g SDS 
57.68 g Glycine  
Made up to 2 L in dH2O 
Can be stored at room temp – will run out before it goes out of date  
 
Sample buffer/Laemmli buffer (X4) 
 
1.51g Tris Base 
20ml Glycerol  
Add 25 ml dH20 and adjust to pH 6.8  
Then add 4 g SDS  
10 ml 2-mercaptoethanol  
0.004 g bromophenol blue  
Make up to 100 ml with dH2O  
Filter and store in -20 in aliquots  
 
Towbin Buffer 
 
1.51 g Tris Base 
7.2 g Glycine  
0.167 g SDS 
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75 ml Methanol  
Make up to 500 ml with dH2O 
Adjust pH to 8.3 and store at room temperature 
 
 
Bovine Serum Albumin (for Blocking and Antibody solutions) 
 
1% solution – add 1 g BSA to 100 ml PBS-T  
Store in fridge for approx. a week 
 
Milk (for Blocking and Antibody solutions) 
 
5% solution – add 5 g milk powder to 100 ml PBS-T 
Store in fridge for approx. a week 
 
Stripping Buffer 
 
0.9 g Tris-HCL  
2 g SDS 
Add 100 ml of dH2O and adjust pH to 6.7 
Then add 800 uL 2-mercaptoethanol 
 
TBS-T 
 
2.422 g Tris base 
16.36 g NaCL 
2 ml Tween 
In 2 L dH2O 
Adjust to pH 7.4 and store at room temperature for 7-10 days or at 4°C for a 
month. 
 
RIPA Lysis Buffer 
 
50 mM Tris base adjusted to pH 8 (0.607g) 
150 mM NaCL (0.292g) 
0.5% Sodium deoxycholate (0.5g) 
0.1% SDS (0.1g) 
1% Triton X-100 (1ml) 
Make up to 100ml with dH2O 
 
Immunocytochemistry recipes 
 
Blocking buffer 
 
5% goat serum  
Made up in PBS-T  
 
Blocking buffer with additional ingredients 
 
10% horse serum 
0.3 M glycine 
1% bovine serum albumin 
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In PBS-T (1%) 
Other 
 
Tris-Borate-EDTA buffer (TBE) 
 
89 mM Tris (pH 7.6) 
89 mM boric acid 
2 mM EDTA 
In dH2O 
 
Standard cell culture media 
 
440 ml DMEM high glucose 
5 ml L-glutamine 
50 ml heat inactivated foetal bovine serum 
5 ml penicillin-streptomycin  
Filtered through 0.22 µm filter 
 
Neutral buffered formalin (10%) 
 
50 ml formaldehyde (37% solution) 
3.25 g dibasic sodium phosphate  
2 g monobasic sodium phosphate 
In 500 ml dH2O 
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3 
Polymerase Chain Reaction  
 
Table 8. Oxytocin receptor primers. 
Target Gene Forward Primer Reverse Primer Amplicon 
Size 
Oxytocin 
Receptor 
(OXTR 1) 
CCGCACGGTCAAGA
TGACTT 
ATGAAGGCCGAGGCT
TCCTTG 
123 
Oxytocin 
Receptor 
(OXTR 2) 
CAAGCTCATCTCCAA
GGCCA 
GAAGGCCGAGGCTTC
CTTG 
145 
Oxytocin 
Receptor 
(OXTR 3) 
GTCTACATCGTGCC
GGTCAT 
TGAAGGCCGAGGCTT
CCTTG 
313 
Oxytocin 
Receptor 
(OXTR 4) 
TGCTGGACGCCTTT
CTTCTT 
GAAGGCCGAGGCTTC
CTT 
75 
Oxytocin 
Receptor 
(OXTR 5) 
CGCCCAAGGAAGCC
TCG 
GGCTCAGGACAAAGG
AGGAC 
213 
Oxytocin 
Receptor 
(OXTR 6) 
GACGCCTTTCTTCTT
CGTGC 
ATGAAGGCCGAGGCT
TCCTTG 
72 
 
 
 
Figure 26. Agarose gel electrophoresis (2%) of end-point 
polymerase chain reaction optimising oxytocin receptor 
primers and no template controls. Primers 1-6 optimised using 
cDNA extracted from human breast cancer MCF-7 cells and primers 
(1-6) no template control (NTC). Representative images from N = 1. 
 
Oxytocin receptor primers 1-6 were optimized using RNA extracted from human 
breast cancer MCF-7 cells cultured in standard media and extracted via Trizol 
method and converted to cDNA using Promega’s GoTaq® 2-step RT qPCR kit 
(methods 2.whatever) as a positive control as they are known to express oxytocin 
1    2    3    4    5    6                    1    2    3    4    5    6  
NTC 
76 
 
receptor. Oxytocin receptor primers 2,3 and 5 worked as expected, amplicon size 
was shown via gel electrophoresis, primers 1,4 and 6 showed no amplification. No 
template controls were clear showing no contamination. 
 
 
Figure 27. Agarose gel electrophoresis. Oxytocin primers on human sperm cDNA. 
Contamination present throughout. Primers 2, 3 and 5 optimised using cDNA extracted from 
human sperm cells and primers (2, 3, 5) no template control (NTC). Representative images from N 
= 1. 
2   3   5    2    3   5 
NTC 
